Endocrine Abstracts

Background: There is accumulating evidence suggesting that altered vitamin D may play a role in the development of T2DM. A growing body of evidence suggests that low levels of vitamin D may adversely affect the cardiovascular system.

Objective: This is to assess the relation of serum 25 OH vitamin D concentrations and risk of CVD in T2DM patients.

Subjects and methods: Seventy subjects aged from 40 to 60 years were chosen excluding those with any other chronic illness and those receiving any medication that affects vitamin D metabolism or taking vitamin D supplement. They were divided into: Group I: 20 subjects with T2DM with CVD. Group II: 20 subjects with T2DM without CVD. Group III: 20 non diabetic subjects with CVD. Group IV: 10 healthy subjects. FPG and 2h PPPG, HbA1c, kidney function test, lipid profile, Urinary albumin excretion, hs-CRP, 25OH vitamin D by ELISA, ECG and echocardiography were done for all subjects.

Results: Serum 25 OH vitamin D was lower in T2DM patients with CVD than those without CVD than non diabetic patients with CVD than control subjects (P<0.01). hs-CRP level was significantly higher in T2DM patients with CVD and non diabetic patients with CVD than in T2DM patients without CVD (P<0.01). Microalbuminurea was higher in T2DM patients with CVD than those without CVD and non diabetic patients with CVD (P<0.01). There was significant negative correlation between serum 25 OH vitamin D and age, BMI, waist circumference, systolic blood pressure, diastolic blood pressure, FPG, 2hPPG, HbA1c, TC, TG, LDL-c, hs-CRP and microalbuminurea (P<0.01).

Conclusion: T2DM patients and patients with CVD had a significant reduction in serum 25 OH vitamin D concentrations, so ongoing evaluation of the protective role of vitamin D₃ supplementation in the development of atherosclerosis is needed.